n spite of improvement in perinatal assistance, the frequency of Respiratory Distress Syndrome in preterm babies (NRDS) remains very high. The estimated incidence of NRDS in babies with a birth weight of 500750 g (very low birth weight -VLBW-) reaches a value of over 80% and in babies with a birth weight between 1000 and 1500 g the frequency is over the 30% (1). Survival significantly improved ...

Therapy with exogenous surfactants is currently used for the treatment of respiratory distress syndrome of the newborn (RDS) and is under investigation for treatments related to adult RDS. However, the possible use of exogenous surfactant as a means of enhancing mucus clearance in other respiratory diseases has not been addressed. We therefore studied the effects of an artificial surfactant (Cu...

This paper reports the chemical synthesis and purification of a novel phospholipase-resistant C16:0, C16:1 diether phosphonoglycerol with structural analogy to ester-linked anionic phosphatidylglycerol (PG) in endogenous pulmonary surfactant. This diether phosphonoglycerol (PG 1) is studied for phospholipase A(2) (PLA(2)) resistance and for surface activity in synthetic exogenous surfactants co...

OBJECTIVE To review well-known aspects of exogenous surfactant therapy, and to discuss controversial points regarding the current state of research. SOURCES Review of the literature, using Medline and Cochrane Database Library, in association with the authors' experience in relation to exogenous surfactant replacement therapy. SUMMARY OF THE FINDINGS The main aspects of surfactant character...

Abstract The coronavirus disease 2019 (COVID-19) has led to serious health and economic damage all over the world, it still remains unstoppable. SARS-CoV-2, by using its S-glycoprotein, binds with an angiotensin-converting enzyme 2 receptor, mostly present in alveolar epithelial type II cells. Eventually pulmonary surfactant depletion occurs. is necessary for maintaining natural immunity as wel...